Description
Cagrilintide is a long-acting, 39-amino acid acylated peptide derivative of amylin that acts as a dual amylin and calcitonin receptor agonist (DACRA) for obesity treatment. Its structure is based on pramlintide, featuring key modifications (Asn14Glu, Val17Arg, Pro25/28/29, Tyr37Pro) to improve metabolic stability and reduce aggregation.
Key Structural Details:
- Amino Acid Chain: 39 residues with C-terminal amidation.
- Modifications: Contains 14E (Glu) and 17R (Arg) mutations, along with substitutions (25P/28P/29P) that enhance receptor interaction and decrease fibrillation.
- Acylation: Features a side-chain modification (lipidation) at the N-terminus that extends its half-life.
- Structure: It is a linear polypeptide with a disulphide bridge between positions 2 and 7, similar to amylin.
